Mechanistically, either UV-irradiation or aFP plus imiquimod treatment can improve anti-PD-1 therapeutic efficacy in poorly immunogenic melanomas by expansion of CD8+ T cells capable of recognizing wild-type melanocyte antigens and boosting immune response. Here, CD8A is linked to melanoma.